Association between RA and coeliac disease: CD pts = 57% higher risk of RA vs. matched non-CD pts. Risk associated w/ age aOR 2, female aOR 2.6, socioeconomic status aOR 1.2, Medicaid aOR : 1.3. https://t.co/APdWW7f1U6 Abst #0271 #ACR22 @Rheumnow https://t.co/djriO3QMAh

• Temporal Trends and Risk of Rheumatoid Arthritis in Celiac Disease Patients: A …

Neural networks can delineate different forms of inflammatory arthritis (sero+, sero- & PsA) based on structural/inflammation patterns on MRI. Required use of contrast enhancement. Are we going to be obsolete soon @DrCMcMaster? @RheumNow ABSR0242 #ACR22 https://t.co/JExk9HiIYu https://t.co/G2tCafE8A7

• Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthriti…

#ACR22 Abstr#0004 Macrophage Activation Syndrome is associated with Systemic JIA #arthritis but how do they link up? Mice studies show mTORC1 is a key driver. Studies needed to assess mTORC1-inhibitor e.g. rapamycin, sirolimus etc. for SJIA-related MAS @RheumNow https://t.co/sH9seK1n8u

Why are #sJIA pts prone to #MAS? Potential new treatment target mTORC1? mTORC1 gene signature in monocytes Mice models and human translational studies with evidence #ACRBest #ACR22 @rheumnow abst#0004 #stillsdisease #autoinflammatorydisease https://t.co/Q2ehfyWMKG

Safety data from 9 phase 3 UPA trials (RA, PsA & AS). In 11,271 pt-yrs exposure, no increased signal for cancer (excluding NMSC) cf. ADA/MTX. NMSC was higher however. What data (if any) would reassure people in this space? @RheumNow ABST0292 #ACR22 https://t.co/tS5r66loqP

• Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis…

MIRROR RCT: Pegloticase + MTX 60% response rate vs. 30% Pegloticase + PBO in uncontrolled gout patients. 1/2 patients w/ resolution of >= 1tophus in MTX gpe vs. < 1/3 in PBO. Safety profile comparable between groups. https://t.co/oJ6kYw94L3 Abst#0001 #ACR22 @Rheumnow https://t.co/Hmeym3Cy7n

• 12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicen…

Beautiful translational work looking at mTORC1 driving systemic JIA to MAS - a deadly escalation. An already accessible target: Rapamycin in sJIA a serious proposition! ABST0004 @BostonChildrens #ACR22 @RheumNow https://t.co/fW3C5ludjc

RECITAL trial: First line RTX vs. CYC in ILD 🫁 asso w/ SSc, mixed CTD or Myositis. Primart endpoint FVC 24 wks improved in both mCTD and Myositis associated ILD but only stabilized in SSc-ILD. RTX improved skin thickness 24 wks. https://t.co/MQcqds0jYA Abst#0003 #ACR22 @Rheumnow https://t.co/pK48716nIg

• Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Diseas…

#acrbest #abst0004 #acr22 @rheumnow 🐁 model of excessive mTORC1 activation in JIA confirms unrestricted activation of mTORC1 sufficient to trigger sJIA-like syndrome including MAS w/hemophagocytosis. rapamycin prevents MAS & ⬇️ arthritis severity & bone erosion in Il1rn-/- mice https://t.co/2HSXOJ6tX8

If rheumatologists were distributed equitably in the US, the Navajo nation should have 19 rheumatologists. They have just one. Very exciting scalable program to empower primary care. Enormously powerful, both there and elsewhere ABST0005 @jrmandal @JYazdanyMD #ACR22 @RheumNow https://t.co/mOtgLomZLM

Only small changes in lipid profile and no change in arterial inflammation (measured by FDG-PET) in both TNFi/MTX and triple therapy groups over a 24 week period in the TARGET trial. What do you think could account for this? Follow-up period too short? @RheumNow ABST0254 #ACR22 https://t.co/JMJ7WgXyJX

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty.

What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view. #plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY

Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high risk pts! Can even consider PET/CT, CT, pelvic US, initially. Question is... will insurances approve all of these tests? Abs#0002 @RheumNow #ACR22 https://t.co/uvr4jGVTFP

Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR22 @rheumnow #myositis https://t.co/vJ82rEX2wk